APA (7th ed.) Citation

Alexander, E., Schranz, J., Das, A. F., Moran, G. J., Sandrock, C., File, T. M., & Gelone, S. P. (2019). 664. Efficacy in Adults With Moderate to Severe Community-Acquired Bacterial Pneumonia (CABP) and Pneumonia Outcomes Research Team (PORT) Risk Class III to V: Results of a Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Outcomes. Open Forum Infectious Diseases, 6, S304. https://doi.org/10.1093/ofid/ofz360.732

Chicago Style (17th ed.) Citation

Alexander, Elizabeth, Jennifer Schranz, Anita F. Das, Gregory J. Moran, Christian Sandrock, Thomas M. File, and Steven P. Gelone. "664. Efficacy in Adults With Moderate to Severe Community-Acquired Bacterial Pneumonia (CABP) and Pneumonia Outcomes Research Team (PORT) Risk Class III to V: Results of a Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Outcomes." Open Forum Infectious Diseases 6 (2019): S304. https://doi.org/10.1093/ofid/ofz360.732.

MLA (9th ed.) Citation

Alexander, Elizabeth, et al. "664. Efficacy in Adults With Moderate to Severe Community-Acquired Bacterial Pneumonia (CABP) and Pneumonia Outcomes Research Team (PORT) Risk Class III to V: Results of a Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Outcomes." Open Forum Infectious Diseases, vol. 6, 2019, p. S304, https://doi.org/10.1093/ofid/ofz360.732.